If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

Share Price is delayed by 15 minutes
Get Live Data
0.502    0.00 (0.00%)
Bid:
0.502
Ask:
0.51
Spread: 0.008 (1.594%)
Market Cap: $291.83m
IDHC Live PriceLast checked at - London Stock Exchange

Intraday Int Diag Hld Share Chart

Form 8.3 - Integrated Diagnostics Holdings PLC

Today 07:00

RNS Number : 8749K
337 Frontier Capital LP
02 July 2026
ย 

ย 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

ย 

ย 

1. KEY INFORMATION

ย 

(a) Full name of discloser:

337 Frontier Capital LP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Integrated Diagnostics Holdings PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

1 July 2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

ย N/A

ย 

ย 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

ย 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

ย 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

ย 

Class of relevant security:

ย 

USD 0.25 Ordinary

ย 

ย 

Interests

Short positions

ย 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

64,194,814

ย 

11.04

ย 

ย 

(2) Cash-settled derivatives:

ย 

ย 

ย 

ย 

ย 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

ย 

ย 

ย 

ย 

ย 

TOTAL:

64,194,814

ย 

11.04

ย 

ย 

ย 

All interests and all short positions should be disclosed.

ย 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Formย 8 (Open Positions).

ย 

(b) Rights to subscribe for new securities (including directors' and other employee options)

ย 

Class of relevant security in relation to which subscription right exists:

ย 

Details, including nature of the rights concerned and relevant percentages:

ย 

ย 

ย 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

ย 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

ย 

The currency of all prices and other monetary amounts should be stated.

ย 

(a) Purchases and sales

ย 

Class of relevant security

Purchase/sale

ย 

Number of securities

Price per unit

USD 0.25 Ordinary

Purchase

434,327

0.507

ย 

(b) Cash-settled derivative transactions

ย 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

ย 

ย 

ย 

(c) Stock-settled derivative transactions (including options)

ย 

(i) Writing, selling, purchasing or varying

ย 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

ย 

(ii) Exercise

ย 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

ย 

ย 

ย 

ย 

ย 

ย 

ย 

(d) Other dealings (including subscribing for new securities)

ย 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

ย 

ย 

ย 

ย 

ย 

ย 

ย 

4. OTHER INFORMATION

ย 

(a) Indemnity and other dealing arrangements

ย 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

ย 

None

ย 

ย 

(b) Agreements, arrangements or understandings relating to options or derivatives

ย 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

ย 

None

ย 

ย 

(c) Attachments

ย 

Is a Supplemental Form 8 (Open Positions) attached?

NO

ย 

ย 

Date of disclosure:

02 July 2026

Contact name:

Malini van den Berg

Telephone number*:

+1 646 813 3351

ย 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

ย 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

ย 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

ย 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

ย 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ย 
END
ย 
ย 
RETBIGDRBXGDGLD
Date   Source Headline
5th Oct 202212:49 pmRNSAl-Borg Scan obtains ACR Accreditation
12th Sep 20228:23 amRNSHalf-year Report
7th Sep 20224:04 pmRNSNotice of Results
6th Sep 20229:30 amRNSIDC termination; negotiations ongoing
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
17th Aug 20224:41 pmRNSSecond Price Monitoring Extn
17th Aug 20224:36 pmRNSPrice Monitoring Extension
16th Aug 20222:09 pmRNSIDH CEO ups stake in the Company
16th Aug 202211:19 amRNSDirector/PDMR Shareholding
15th Aug 20224:41 pmRNSSecond Price Monitoring Extn
15th Aug 20224:36 pmRNSPrice Monitoring Extension
11th Aug 20226:01 pmRNSDirector/PDMR Shareholding
11th Aug 20225:44 pmRNSDirector/PDMR Shareholding
9th Aug 20225:27 pmRNSDirector/PDMR Shareholding
9th Aug 20222:50 pmRNSDirector/PDMR Shareholding
5th Aug 20223:27 pmRNSDirector/PDMR Shareholding
4th Aug 20224:09 pmRNSDirector/PDMR Shareholding
3rd Aug 20226:01 pmRNSDirector/PDMR Shareholding
3rd Aug 20224:16 pmRNSDirector/PDMR Shareholding
2nd Aug 202210:43 amRNSDirector/PDMR Shareholding
27th Jul 20229:59 amRNSFinal Dividend Distribution
8th Jun 20228:45 amRNS1st Quarter Results
8th Jun 20227:00 amRNSResult of AGM
1st Jun 20225:39 pmRNSNotice of Results
23rd May 20224:35 pmRNSPrice Monitoring Extension
12th May 20225:37 pmRNSAnnual Financial Report & Notice of AGM
21st Apr 20229:46 amRNSPreliminary Results
31st Mar 202210:04 amRNSIFC and IFC MENA Fund acquire 5% stake in IDH
29th Mar 20228:30 amRNSIDH launches fifth Al-Borg Scan Branch
1st Mar 20222:00 pmRNSDirectorate Change
20th Dec 202110:26 amRNSReplacement: IDH 50% Acquisition of IDC
20th Dec 20218:00 amRNSIDH Acquisition of Islamabad Diagnostic Centre
16th Nov 20217:00 amRNS3rd Quarter Results
12th Nov 202112:03 pmRNSNotice of Results
28th Oct 20214:34 pmRNSNotice of Arbitration
4th Oct 202111:48 amRNSIDH launches third Al-Borg Scan branch
24th Sep 202112:50 pmRNSIDH 1H 2021 Standalone Financial Statements
2nd Sep 20217:00 amRNSHalf-year Report
18th Aug 202110:04 amRNSBiolab to operate testing stations in QAIA
9th Jul 20214:16 pmRNSFinal dividend clarification
30th Jun 202112:21 pmRNSResult of AGM
17th Jun 202110:02 amRNSFinal Dividend Resolution – Date Amendments
7th Jun 20215:24 pmRNSAnnual Financial Report & Notice of AGM
7th Jun 20217:00 amRNSChange of Auditor
2nd Jun 20217:00 amRNS1st Quarter Results
27th May 20215:07 pmRNSShare Transfer Mechanism and Documents
25th May 20217:00 amRNSIDH partners with IFC on USD 45m debt financing
20th May 202111:58 amRNSIDH debuts trading on EGX
19th May 20217:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.